Gastric cancer with high risk of intraperitoneal progression: clinical course and current treatments

1. Siewert JR, Bottcher K, Stein HJ et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228(4):449-461.10.1097/00000658-199810000-0000211915159790335Search in Google Scholar

2. Lim L, Michael M, Mann GB, Leong T. Adjuvant therapy in gastric cancer. J Clin Oncol. 2005;23(25):6220-6232.10.1200/JCO.2005.11.59316135489Search in Google Scholar

3. Yoo CH, Noh SH, Shin DW et al. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87(2):236-242.10.1046/j.1365-2168.2000.01360.x10671934Search in Google Scholar

4. Nered SN, Klimenkov AA. Surgical treatment of gastric cancer with a high risk of implantation metastasis. Questions Oncology. 2005;51(1):75-80.Search in Google Scholar

5. Koga S, Kaibara N, Itsuka Y et al. Prognostic significance of intraperitoneal free cancer cells in gastric cancer patients. J Cancer Res Clin Oncol. 1984;108:236-238.10.1007/BF004024746470030Search in Google Scholar

6. Van den Tole P, Van Rossen E, Van Eijck C et al. Reduction of peritoneal trauma by using non surgical gauze leads to less implantation metastases of spilled tumour cells. Ann Surg. 1998;227(2):242-248.10.1097/00000658-199802000-0001411912429488523Search in Google Scholar

7. Chen S, Cai MY, Chen YB et al. Serosa-penetration in human T4aN0M0 gastric carcinoma correlates with worse prognosis after D2 gastrectomy. Chin Med J. 2012;125(6):1158-1162.Search in Google Scholar

8. Maekawa S, Saku M, Maehara Y et al. Surgical treatment for advanced gastric cancer. Hepatogastroenterology. 1996;43(7):178-186.Search in Google Scholar

9. Arhelger SW. Advances in diagnosis and management of gastric cancer: II. Trends in the management of gastric csncer. CA Cancer J Clin. 1957;7:161-170.10.3322/canjclin.7.5.16113472462Open DOISearch in Google Scholar

10. Cunningam D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastro-esophageal cancer. N Engl J Med. 2006;355(1):11-20.10.1056/NEJMoa05553116822992Search in Google Scholar

11. MacDonald JS, Malley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725-730.10.1056/NEJMoa01018711547741Search in Google Scholar

12. Wu CW, Lo Wu SS, Shen KH et al. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg. 2003;27(2):153-158.10.1007/s00268-002-6279-712616428Search in Google Scholar

13. Bentrem D, Wilton A, Mazumdar M et al. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol. 2005;12(5):347-353.10.1245/ASO.2005.03.06515915368Open DOISearch in Google Scholar

14. Saito H, Kuroda H, Matsunaga T et al. Prognostic indicators in node-negative advanced gastric cancer patients. J Surg Oncol. 2010;101(7):622-625.10.1002/jso.21562Search in Google Scholar

15. Maehara Y, Hasuda S, Koga T et al. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg. 2000;87(3):353-357.10.1046/j.1365-2168.2000.01358.xSearch in Google Scholar

16. Marrelli D, Roviello F, de Manzoni G et al. Different patterns of recurrence in gastric cancer depending on Lauren’s histological type: longitudinal study. World J Surg. 2002;26(9):1160-1165.10.1007/s00268-002-6344-2Open DOISearch in Google Scholar

17. Roviello F, Marrelli D, de Manzoni G et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003;90(9):1113-1119.10.1002/bjs.4164Search in Google Scholar

18. Li H, Zhang SW, Liu J et al. Review of clinical investigation on recurrence of gastric cancer following curative resection. Chin Med J. 2012;125(8):1479-1495.Search in Google Scholar

19. Sobin LH, Gospodarowicz MK, Wittekind Ch, International Union against Cancer. TNM: Classification of malignant tumors, 7th edition, 2009. Chichester, West Sussex, UK, Hoboken NJ: Wiley-Blackwell;2010:310.10.1002/9780471420194.tnmc55.pub2Search in Google Scholar

20. Schwarz RE, Zagala-Nevarez K. Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy. Ann Surg Oncol. 2002;9(4):394-400.10.1007/BF02573875Open DOISearch in Google Scholar

21. Skoropad VY, Berdov BA. Influence of the morphological structure of stomach cancer on patterns of recurrence and metastasis. Questions Oncology. 2009;55(1):60-65.Search in Google Scholar

22. La Torre M, Ferri M, Giovagnoli MR et al. Peritoneal wash cytology in gastric carcinoma. Prognostic significance and therapeutic consequences. Eur J Surg Oncol. 2010;36(10):982-986.10.1016/j.ejso.2010.06.007Search in Google Scholar

23. Nered SN. Surgical and combined treatment of gastric cancer with a high risk of implantation metastasis and resected gastric cancer: Authoref. of thesis on scientific degree dr. med. sciences. Moscow;2004:21 p.Search in Google Scholar

24. D’Ugo D, Persiani R, Ojetti V et al. Prediction of lymph node metastasis in gastric cancer. The 8th International gastric cancer congress (IGCC): abstract book. – Krakow (Poland), 2009, 58.Search in Google Scholar

25. Bando E, Yonemura Y, Takeshita Y et al. Intraoperative lavage for cytological examination in 1297 patients with gastric carcinoma. Am J Surg. 1999;178(3):256-262.10.1016/S0002-9610(99)00162-2Search in Google Scholar

26. Kaibara N, Iitsuka Y, Kimura A et al. Relationship between the area of serosal invasion and prognosis in patients with gastric carcinoma. Cancer. 1987;60(1):136-139.10.1002/1097-0142(19870701)60:1<136::AID-CNCR2820600125>3.0.CO;2-XSearch in Google Scholar

27. Ikeguchi M, Kondou A, Oka A et al. Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Eur J Surg. 1995;161:581-586.Search in Google Scholar

28. Adachi Y, Yasuda K, Inomata M et al. Pathology and prognosis of gastric carcinoma. Well versus poorly differentiated type. Cancer. 2000;89(7):1418-1424.10.1002/1097-0142(20001001)89:7<1418::AID-CNCR2>3.0.CO;2-ASearch in Google Scholar

29. Skoropad VY, Berdov BA. Clinico-morphological parallels in patients with gastric cancer. Questions Oncology. 2009;55(2):165-170.Search in Google Scholar

30. Fukagawa T, Katai H, Saka M et al. Significance of lavage cytology in advanced gastric cancer patients. World J Surg. 2010;34(3):563-568.10.1007/s00268-009-0355-1Open DOISearch in Google Scholar

31. Moriguchi S, Maehara Y, Korenaga D et al. Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. Surg Oncol. 1992;1(5):341-346.10.1016/0960-7404(92)90034-ISearch in Google Scholar

32. Japanese Gastric Cancer Association: Japanese classification of gastric cancer. – 2nd English ed. Gastric Cancer. 1998;1(1):10-24.10.1007/PL00011681Search in Google Scholar

33. Nered SN, Klimenkov AA, Stilidi IS. Signet-ring cell gastric cancer: clinical and morphological aspects, the results of surgical treatment and prognosis. Questions Oncology. 2006;52(3):294-300.Search in Google Scholar

34. Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006;24(14): 2188-2196.10.1200/JCO.2006.05.975816682738Search in Google Scholar

35. Hermans J, Bonenkamp JJ, Boon MC et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1993;11(8):1441-1447.10.1200/JCO.1993.11.8.14418336183Search in Google Scholar

36. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg. 2002;168(11):597-608.10.1080/1102415020168000512699095Search in Google Scholar

37. Sacuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810-1820.10.1056/NEJMoa07225217978289Search in Google Scholar

38. Fujitani K, Sasako M, Iwasaki Y et al. A phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically respectable type 4 and large type 3 gastric cancer: JCOG 0210. J Clin Oncol. 2007;25:4609 abstract. [2007 ASCO Meeting proceedings (post-meeting edition)].10.1200/jco.2007.25.18_suppl.4609Search in Google Scholar

39. Yoshikawa T, Omura K, Kobayashi O et al. A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study). Eur J Surg Oncol. 2010;36(6):546-551.10.1016/j.ejso.2010.04.01120541062Open DOISearch in Google Scholar

40. Sugarbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology. 2000;58(2):96-107.10.1159/00001208610705236Open DOISearch in Google Scholar

41. Chua TC. Progress in the combined modality management of peritoneal carcinomatosis. J Surg Oncol. 2010;102(7):728-729.10.1002/jso.21748Open DOISearch in Google Scholar

42. Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc. 1955;159(18):1704-1707.10.1001/jama.1955.02960350004002Search in Google Scholar

43. Kimura T, Koyama Y. Preventive chemotherapy after radical operations in stomach cancer. Adv Med Oncol. 1979;9:255-268.Search in Google Scholar

44. Spratt JS, Adcock RA, Muskovin M et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40(2): 256-260.Search in Google Scholar

45. Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol. 1985;12(3):1-6.Search in Google Scholar

46. De Roover A, Detroz B, Detry O et al. Adjuvant hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) associated with curative surgery for locally advanced gastric carcinoma. An initial experience. Acta Chir Belg. 2006;106(3):297-301.Search in Google Scholar

47. Fujimoto S, Takahashi M, Mutou T et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer. 1999;85(3):529-534.10.1002/(SICI)1097-0142(19990201)85:3<529::AID-CNCR3>3.0.CO;2-9Search in Google Scholar

48. Yonemura Y, de Aretxabala X, Fujimura T et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterol. 2001;48(42):1776-1782.Search in Google Scholar

49. Kim JY, Rhew CH, Kim KS et al. Controlled clinical trial for the gastric carcinoma patients underwent surgery plus IHCP. The 3th International gastric cancer congress (IGCC): abstract book – Seoul (Korea). 1999;106.Search in Google Scholar

50. Xu DZ, Zhan YQ, Sun XW et al. Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J Gastroenterol. 2004;18:2727-2730.10.3748/wjg.v10.i18.2727Open DOISearch in Google Scholar

51. Yan TD, Black D, Sugarbaker PH et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for respectable gastric cancer. Ann Surg Oncol. 2007;14(10):2702-2713.10.1245/s10434-007-9487-4Search in Google Scholar